[go: up one dir, main page]

EA199900356A1 - Антагонисты рецептора витронектина - Google Patents

Антагонисты рецептора витронектина

Info

Publication number
EA199900356A1
EA199900356A1 EA199900356A EA199900356A EA199900356A1 EA 199900356 A1 EA199900356 A1 EA 199900356A1 EA 199900356 A EA199900356 A EA 199900356A EA 199900356 A EA199900356 A EA 199900356A EA 199900356 A1 EA199900356 A1 EA 199900356A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antagonists
vitronectin receptor
treatment
vitronectin
antigenesis
Prior art date
Application number
EA199900356A
Other languages
English (en)
Other versions
EA002419B1 (ru
Inventor
Джеймс Френсиз Каллахан
Расселл Донован Каузинс
Ричард МакКаллок Кинан
Чет Квон
Вилльям Генри Миллер
Ирен Нийоль Узинкас
Original Assignee
Смитклайн Бичам Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Смитклайн Бичам Корпорейшн filed Critical Смитклайн Бичам Корпорейшн
Publication of EA199900356A1 publication Critical patent/EA199900356A1/ru
Publication of EA002419B1 publication Critical patent/EA002419B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Раскрываются соединения, включающие в свою структуру бензодиазепиновое ядро, которые являются антагонистами витронектина и используются при лечении остеопороза, при антиогенезе, росте опухоли и образовании метастазов, при лечении атеросклероза, рестеноза и воспаления.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199900356A 1996-10-02 1997-10-01 Антагонисты рецептора витронектина EA002419B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2732096P 1996-10-02 1996-10-02
US4377697P 1997-04-11 1997-04-11
PCT/US1997/018001 WO1998014192A1 (en) 1996-10-02 1997-10-01 Vitronectin receptor antagonists

Publications (2)

Publication Number Publication Date
EA199900356A1 true EA199900356A1 (ru) 2000-02-28
EA002419B1 EA002419B1 (ru) 2002-04-25

Family

ID=26702318

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199900356A EA002419B1 (ru) 1996-10-02 1997-10-01 Антагонисты рецептора витронектина

Country Status (37)

Country Link
EP (1) EP0957917B1 (ru)
JP (2) JP4491072B2 (ru)
KR (1) KR100589578B1 (ru)
CN (1) CN1114403C (ru)
AP (1) AP1463A (ru)
AR (1) AR008878A1 (ru)
AT (1) ATE312089T1 (ru)
AU (1) AU733417B2 (ru)
BG (1) BG64581B1 (ru)
BR (1) BR9712248B1 (ru)
CA (1) CA2267224C (ru)
CO (1) CO4900046A1 (ru)
CY (1) CY2576B1 (ru)
CZ (1) CZ299076B6 (ru)
DE (1) DE69734833T2 (ru)
DK (1) DK0957917T3 (ru)
DZ (1) DZ2320A1 (ru)
EA (1) EA002419B1 (ru)
ES (1) ES2252775T3 (ru)
HK (1) HK1023730A1 (ru)
HU (1) HU229221B1 (ru)
ID (1) ID19623A (ru)
IL (1) IL129243A (ru)
MA (1) MA24361A1 (ru)
MY (1) MY137606A (ru)
NO (1) NO320194B1 (ru)
NZ (1) NZ334953A (ru)
PE (1) PE10499A1 (ru)
PL (1) PL190859B1 (ru)
RO (1) RO119881B1 (ru)
SA (1) SA98180936B1 (ru)
SK (1) SK285029B6 (ru)
TR (1) TR199900737T2 (ru)
TW (1) TW487702B (ru)
UA (1) UA60311C2 (ru)
UY (2) UY24735A1 (ru)
WO (1) WO1998014192A1 (ru)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60311C2 (ru) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагонисты рецептора витронектина
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
HUP0003949A2 (hu) * 1997-09-24 2001-10-28 Smithkline Beecham Corp. Vitronektin receptor antagonisták, valamint a vegyületeket tartalmazó gyógyszerkészítmények
IL135188A0 (en) * 1997-09-24 2001-05-20 Smithkline Beecham Corp Vitronectin receptor antagonist
US6372719B1 (en) 1998-03-04 2002-04-16 Jay Cunningham ανβ3 integrin antagonists in combination with chemotherapeutic agents
DE19842415A1 (de) * 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
JP2002533406A (ja) * 1998-12-23 2002-10-08 ジー．ディー．サール ＆ カンパニー 新生物の治療における併用療法として、金属プロティナーゼ抑制剤および一またはそれ以上の抗新生物剤を用いる方法
WO2000046215A1 (en) * 1999-02-03 2000-08-10 Merck & Co., Inc. Benzazepine derivatives as alpha-v integrin receptor antagonists
IL146222A0 (en) * 1999-04-30 2002-07-25 Univ Michigan Therapeutic applications of pro-apoptotic benzodiazepines
EP1208101A4 (en) * 1999-08-06 2003-03-19 Smithkline Beecham Corp VITRONECTIN RECEPTOR ANTAGONISTS USEFUL FOR THE TREATMENT OF VASCULAR ACCIDENTS
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
DE10028575A1 (de) 2000-06-14 2002-03-14 Basf Ag Integrinliganden
DE10027514A1 (de) * 2000-06-06 2002-01-03 Basf Ag Liganden von Integrinrezeptoren
FR2806082B1 (fr) * 2000-03-07 2002-05-17 Adir Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MXPA03006772A (es) 2001-01-29 2004-10-15 Dimensional Pharm Inc Indoles sustituidos y su uso como antogonistas de integrina.
NZ528577A (en) * 2001-04-10 2005-01-28 Smithkline Beecham Corp Method of inhibiting adhesion formation
SE0101386D0 (sv) 2001-04-20 2001-04-20 Astrazeneca Ab New compounds
JP2004528373A (ja) * 2001-05-03 2004-09-16 メルク　エンド　カムパニー　インコーポレーテッド ベンズアゼピノンαＶインテグリン受容体拮抗物質
KR20040058229A (ko) 2001-10-22 2004-07-03 더 스크립스 리서치 인스티튜트 항체 표적화 화합물
GB0215867D0 (en) * 2002-07-09 2002-08-14 Glaxosmithkline Spa Novel method and compounds
JP2006522139A (ja) * 2003-04-04 2006-09-28 スミスクライン・ビーチャム・コーポレイション ベンズアゼピンの製造方法およびその中間体
AU2012216372B2 (en) * 2004-04-02 2015-01-22 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
ES2671522T3 (es) * 2004-04-02 2018-06-06 The Regents Of The University Of California Métodos y composiciones para tratar y prevenir una enfermedad asociada con la integrina alfa V beta 5
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
WO2006069079A2 (en) * 2004-12-21 2006-06-29 Smithkline Beecham Corporation Methods and formulations
JP5180834B2 (ja) * 2005-11-29 2013-04-10 スミスクライン ビーチャム コーポレーション 治療方法
WO2009061448A2 (en) 2007-11-08 2009-05-14 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
EP2221308B1 (en) 2007-11-16 2013-07-10 Ube Industries, Ltd. Benzazepinone compound
US8076475B2 (en) * 2008-03-06 2011-12-13 Glaxosmithkline Llc Process
WO2010093706A2 (en) 2009-02-10 2010-08-19 The Scripps Research Institute Chemically programmed vaccination
WO2010113958A1 (ja) * 2009-03-30 2010-10-07 宇部興産株式会社 眼の疾患の治療又は予防のための医薬組成物
JP5572996B2 (ja) * 2009-05-15 2014-08-20 宇部興産株式会社 ベンズアゼピノン化合物を有効成分として含有する医薬
US10087252B2 (en) 2009-07-24 2018-10-02 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with αvβ5 integrin
EP2501387B1 (en) 2009-11-17 2016-07-27 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
EP2325194A1 (en) * 2009-11-24 2011-05-25 Glycotope GmbH Process for the purification of glycoproteins
US10328082B2 (en) 2014-05-30 2019-06-25 Pfizer Inc. Methods of use and combinations
CA3172692C (en) * 2020-04-26 2024-05-14 Jiangsu Nhwa Pharmaceutical Co., Ltd 1,5-dihydro-2,4-benzodiazepine-3-one derivative and application thereof
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014776A2 (en) * 1992-12-21 1994-07-07 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
MX9700041A (es) * 1994-06-29 1997-04-30 Smithkline Beecham Corp Antagonistas de receptor de vitronectina.
EP0762882A4 (en) * 1994-06-29 2002-09-11 Smithkline Beecham Corp Vibronectin Receptor Antagonists
JPH10504825A (ja) * 1994-08-22 1998-05-12 スミスクライン・ビーチャム・コーポレイション 二環式化合物
WO1996026190A1 (en) * 1995-02-22 1996-08-29 Smithkline Beecham Corporation Integrin receptor antagonists
UA60311C2 (ru) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагонисты рецептора витронектина

Also Published As

Publication number Publication date
BG64581B1 (bg) 2005-08-31
ATE312089T1 (de) 2005-12-15
HUP9903769A2 (hu) 2000-03-28
HU229221B1 (en) 2013-09-30
BG103299A (en) 2000-01-31
AP1463A (en) 2005-09-10
HUP9903769A3 (en) 2000-07-28
NO991590D0 (no) 1999-03-31
SK42599A3 (en) 1999-12-10
DZ2320A1 (fr) 2002-12-28
CZ113299A3 (cs) 2000-03-15
CA2267224A1 (en) 1998-04-09
IL129243A (en) 2004-07-25
AU733417B2 (en) 2001-05-17
UY24935A1 (es) 2001-07-31
NO320194B1 (no) 2005-11-14
BR9712248A (pt) 1999-08-24
CZ299076B6 (cs) 2008-04-16
ID19623A (id) 1998-07-23
AR008878A1 (es) 2000-02-23
CN1114403C (zh) 2003-07-16
EA002419B1 (ru) 2002-04-25
JP2010006838A (ja) 2010-01-14
NZ334953A (en) 2000-01-28
UY24735A1 (es) 1998-03-30
TR199900737T2 (xx) 1999-07-21
NO991590L (no) 1999-05-31
TW487702B (en) 2002-05-21
CA2267224C (en) 2007-03-13
EP0957917B1 (en) 2005-12-07
CN1238689A (zh) 1999-12-15
PL332674A1 (en) 1999-09-27
EP0957917A4 (en) 2002-05-15
PL190859B1 (pl) 2006-02-28
PE10499A1 (es) 1999-03-27
MY137606A (en) 2009-02-27
JP2001501936A (ja) 2001-02-13
JP4491072B2 (ja) 2010-06-30
KR20000048816A (ko) 2000-07-25
UA60311C2 (ru) 2003-10-15
HK1023730A1 (en) 2000-09-22
CY2576B1 (en) 2008-07-02
RO119881B1 (ro) 2005-05-30
AU4746297A (en) 1998-04-24
KR100589578B1 (ko) 2006-06-15
BR9712248B1 (pt) 2010-06-29
WO1998014192A1 (en) 1998-04-09
MA24361A1 (fr) 1998-07-01
SA98180936B1 (ar) 2006-05-30
EP0957917A1 (en) 1999-11-24
ES2252775T3 (es) 2006-05-16
CO4900046A1 (es) 2000-03-27
DE69734833T2 (de) 2006-07-13
IL129243A0 (en) 2000-02-17
DK0957917T3 (da) 2006-04-18
AP9901493A0 (en) 1999-03-31
DE69734833D1 (de) 2006-01-12
SK285029B6 (sk) 2006-04-06

Similar Documents

Publication Publication Date Title
EA199900356A1 (ru) Антагонисты рецептора витронектина
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
EA199801031A1 (ru) Ингибиторы протеинфарнезилтрансферазы
MX9805255A (es) Antagonistas de receptor de vitronectina.
PL331091A1 (en) Therapeutic multispecific compounds encompassing antibodies against the fcalpha receptor
CU23126A3 (es) Inhibicion de kinasa raf usando ureas heterociclicas sustituidas
DE60033030D1 (de) Verwendung von gegen cd20 gerichteten antikörpern zur behandlung der graft versus host krankheit
DE69711011D1 (de) Zementzusatz, dessen Herstellungsverfahren und dessen Verwendung
EA200000381A1 (ru) Препарат 2-метил-тиено-бензодиазепина
DK1140173T4 (da) Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf
EA199900630A1 (ru) Антагонисты рецепторов витронектина
PT1131291E (pt) Antagonistas iii do receptor 4-aroil-piperidin-ccr-3
ATE228502T1 (de) Substituierte analoge von indol-3-carbinol und von diindolmethan als antiestrogene
DE69630955T2 (de) Immortalisierung bzw. desimmortalisierung von zellen
DE60035057D1 (de) CD40 Antagonist zur Behandlung von Psoriasis
MX9303594A (es) Oximas piridino, pirrolidino y azepino substituidas utiles como agentes antiateroscleroticos y antihipercolesterolemicos.
AR016981A2 (es) Polipeptidos sinteticos
TR200002625T2 (tr) Vitronektin Reseptörü Antagonistleri
DE69524623D1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
BR0009767A (pt) Agentes inibitórios e quimiotáticos derivados de osteopontina e seus usos
EA199800867A1 (ru) Соединения тетрагидробетакарболина
PT840620E (pt) Antagonistas de il-8 para o tratamento de asma
ATE242215T1 (de) Fluoralkyl- und fluoralkoxysubstituierte hetero- cyclische bradykinin-antagonisten
EA200100854A1 (ru) Кальций-литические соединения
ES2192610T3 (es) Aminouracilos substituidos.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU